Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 11.63 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $26.65 million which beat the analyst consensus estimate of $24.03 million by 10.89 percent. This is a 3.77 percent decrease over sales of $27.69 million the same period last year.
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato
